Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.19 (
NOS
)
7,285
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The objective of the present study was to study the electrophysiological effects of agmatine on human atrial fibers obtained at cardiac surgery using standard microelectrode techniques. Agmatine (1 to approximately 10 mM) decreased the action potential amplitude (APA), maximum upstroke velocity of phase 0 depolarization (Vmax), velocity of diastolic (phase 4) depolarization (VDD), rate of pacemaker firing (RPF), and action potential duration at 50 and 90% of repolarization (
APD
(50-90)) in a concentration-dependent manner. Pretreatment with N(G)-nitro-L-arginine methyl ester (L-NAME, 0.5 mM), a
NOS
inhibitor, did not affect the electrophysiological effects of agmatine (5 mM) on human atrial fibers. The effects of agmatine (5 mM) could be blocked completely by pretreatment with idazoxan (0.1 mM), an alpha-2 adrenergic receptor (alpha2-AR) and imidazoline receptor (IR) antagonist. All these results indicate that the effects of agmatine on human atrial fibers are likely due to a decrease of intracellular calcium mediated by IR and/or alpha2-AR.
...
PMID:Electrophysiological effects of agmatine on human atrial fibers. 1086 97